The development of antiviral treatment and anticancer theragnostic agents in recent decades has been associated with nanotechnologies, and primarily with inorganic nanoparticles (INPs) of metal and metal oxides. The large specific surface area and its high activity make it easy to functionalize INPs with various coatings (to increase their stability and reduce toxicity), specific agents (allowing retention of INPs in the affected organ or tissue), and drug molecules (for antitumor and antiviral therapy). The ability of magnetic nanoparticles (MNPs) of iron oxides and ferrites to enhance proton relaxation in specific tissues and serve as magnetic resonance imaging contrast agents is one of the most promising applications of nanomedicine. Activation of MNPs during hyperthermia by an external alternating magnetic field is a promising method for targeted cancer therapy. As therapeutic tools, INPs are promising carriers for targeted delivery of pharmaceuticals (either anticancer or antiviral) via magnetic drug targeting (in case of MNPs), passive or active (by attaching high affinity ligands) targeting. The plasmonic properties of Au nanoparticles (NPs) and their application for plasmonic photothermal and photodynamic therapies have been extensively explored recently in tumor treatment. The Ag NPs alone and in combination with antiviral medicines reveal new possibilities in antiviral therapy. The prospects and possibilities of INPs in relation to magnetic hyperthermia, plasmonic photothermal and photodynamic therapies, magnetic resonance imaging, targeted delivery in the framework of antitumor theragnostic and antiviral therapy are presented in this review.

No abstract

Aim of the study. We attempted to obtain the Mn-HMPAO complex (Mangoxim) and to evaluate the possibility to apply as a paramagnetic contrast agent for enhancement of tumors at MRI. Materials and methods. The synthesis of HMPAO was carried out by using R. D. Neirinckx — J. Pijarowska-Kruszyna technique (2017), without separation of enantiomers. The Mn-HMPAO was obtained by mixing Manganese(II) carbonate with HMPAO, pH 6,2–6,5, 0,5 M. Also the quantum chemistry calculations were carried out on the structure of Mn-HMPAO using method of functional of density DFT rb3lyp/6–31+g(d,p) for isolated molecules and for water solutions (CPCM). MRI study of Mn-HMPAO uptake carried out in twelve laboratory mouses with transplanted Lewis sarcoma, in T1-w. SE mode, TR=500 ms, TE=15 ms, 256×256 matrix, FOV 15×15 cm, 3 mm thin slice. MRI acquired in 15–17 min and 60–90 min after intravenous injection of the Mn-HMPAO. The uptake was quantified as index of enhancement: IE=(Int. T1-w.MRI)Mn-HMPAO/(Int. T1- w.MRI)pre-contrast. Results. The N,N-Mn-dioxim is more stable than O,O-Mn-dioxim for 50,5 KCal/mol, so in the nature only N,N-Mn-dioxim exists. R1 of Mn-HMPAO was 3,35 1/(mM•s), below R1 of gadopentetate=3,96 1/(mM•s). The highest value of early IE was over the tumor (3,36±0,31) and over lungs (3,07±0,43). At 60 min the IE over tumor decreased to 1,58±0,14, remaining far over IE values over any other location. Conclusion. The Mn-HMPAO complex demonstrates paramagnetic properties for the application as the contrast MRI agent and probably will improve the selective enhancement of tumors.

Cortisol in concentrations within the therapeutic range inhibits calcium response of fibroblast to angiotensin II. In physiological concentrations, cortisol potentiates the effects of angiotensin II via modulation of membrane mineralocorticoid receptors. The inhibitory effects of glucocorticoids on cell proliferation and collagen synthesis are manifestations of its genomic effects mediated by intracellular receptors. The use of glucocorticoid preparation based on nanosized polymer structure made it possible to distinguish between the genomic and nongenomic mechanisms of regulation of activity of target-cells.

Aim of the study. We have carried out the synthesis of complex of Manganese(II) with dimercaptosuccinic acid (DMSA), applied the quantum chemistry analysis for evaluation of most stable form of the Mn- DMSA complex and studied it’s uptake and imaging properties in normal and tumoral tissues in veterinary patients (cats with tumors)Material and methods. The synthesis of the 2.3-dimercaptosuccinic acid (COOH-CHSH-CHSH-COOH) has been carried out using modified technique proposed by A.I. Busev [Busev A.I. 1972]. Using phantoms filled in with 0.05 mM – 16 mM solutions of the agent we quantified the R1 relaxivity. Imaging properties of the 0.5 M solution of the Mn-(DMSA)2 were evaluated when performing the  contrastenhanced studies in veterinary patients (cats with adenofibrous tumors and angiofibromas, nine animals) using T1-w spin-echo mode.Results. As result of quantum chemistry analysis it was shown that the most stable complex of Mn(II) with DMSA is the molecule Mn-(DMSA)2. The R1 relaxivity of the Mn-(DMSA)2 complex in the water solution was as high as 3.2 1/(mM*s). In normal control animals the Mn-(DMSA)2 provided highly intensive enhancement of renal parenchyma and mild enhancement of liver, spleen and bone marrow. In animals with tumors the Mn-(DMSA)2 enhanced the T1-w spin-echo images of angiofibromas and fibroadenomas in both peripheral (index of enhancement = 1.87 ± 0.09, p < 0.01) and central (index of enhancement = 1.59 ± 0.07, p < 0.01) parts of the tumor.Conclusion. The imaging properties of the Mn-(DMSA)2 make an argue for real possibility of production of new non-Gadolinium paramagnetic contrast agents specific to tumors. Further study of the Mn-(DMSA)2 complex as paramagnetic contrast agent is of interest and useul.